Tagashira H, Bhuiyan MS, Fukunaga K. Diverse regulation of IP3 and ryanodine receptors by pentazocine through 1-receptor in cardiomyocytes. Am J Physiol Heart Circ Physiol 305: H1201-H1212, 2013. First published August 9, 2013; doi:10.1152/ajpheart.00300.2013.-Although pentazocine binds to 1-receptor (1R) with high affinity, the physiological relevance of its binding remains unclear. We first confirmed that 1R stimulation with pentazocine rescues contractile dysfunction following pressure overload (PO)-induced cardiac hypertrophy ovariectomized (OVX) female rats. In in vivo studies, vehicle, pentazocine (0.5-1.0 mg/kg ip), and NE-100 (1.0 mg/kg po), a 1R antagonist, were administered for 4 wk (once daily) starting from the onset of aortic banding after OVX. We also examined antihypertrophic effects of pentazocine (0.5-1 M) in cultured cardiomyocytes exposed to angiotensin II. Pentazocine administration significantly inhibited PO-induced cardiac hypertrophy and rescued hypertrophyinduced impairment of cardiac dysfunctions such as left ventricular end-diastolic pressure, left ventricular developed pressure, and left ventricular contraction and relaxation (Ϯdp/dt) rates. Coadministration of NE-100 with pentazocine eliminated pentazocine-induced amelioration of heart dysfunction. Interestingly, pentazocine administration inhibited PO-induced 1R reduction and inositol-1,4,5-trisphosphate (IP 3) receptor type 2 (IP3R2) upregulation in heart. Therefore, the reduced mitochondrial ATP production following PO was restored by pentazocine administration. Furthermore, we found that 1R binds to the ryanodine receptor (RyR) in addition to IP3 receptor (IP 3R) in cardiomyocytes. The 1R/RyR complexes were decreased following OVX-PO and restored by pentazocine administration. We noticed that pentazocine inhibits the ryanodine-induced Ca 2ϩ release from sarcoplasmic reticulum (SR) in cultured cardiomyocytes. Taken together, the stimulation of 1R by pentazocine rescues cardiac dysfunction by restoring IP 3R-mediated mitochondrial ATP production and by suppressing RyR-mediated Ca 2ϩ leak from SR in cardiomyocytes. 1 receptor; pentazocine; myocardial hypertrophy; ATP; ryanodine receptor; inositol-1,4,5-trisphosphate receptor THE RACEMIC COMPOUND (Ϯ) pentazocine, a nonnarcotic analgesic, is used for the management of moderate to severe pain in humans, including those with cardiac operation and heart failure (14, 16, 24) . However, there is little evidence regarding pentazocine action on myocardial contractility in heart because of lacking in vivo studies using rodents. In isolated cardiomyocytes, 1 nM of (ϩ) pentazocine slightly reduces contraction amplitude, whereas 10 nM of the drug increases contraction amplitude. The increase in contraction amplitude is transient (23). The ameliorated effect of pentazocine after cardiac ischemia is reported in the Langendorff-perfused isolated heart preparation (27). Moreover, pentazocine shows cardioprotective effects in human or rodents after cardiac surgery (3, 14, 21, 33) . Although the previous studies suggested that pentazocine regulates Ca 2ϩ mobilization from sarcoplasmic reticulum (SR)/endoplasmic reticulum (ER) through opioid or -1 receptors ( 1 R) (8, 23), the precise cardioprotective mechanisms of pentazocine in cardiomyocytes remain unclear. Because pentazocine is a weak competitive antagonist of the -type opioid receptor and strong agonist for -and ␦-receptors (9) in addition to a potent 1 R agonist (19), it is important to define which receptors mediate pentazocine-induced cardioprotection.
THE RACEMIC COMPOUND (Ϯ) pentazocine, a nonnarcotic analgesic, is used for the management of moderate to severe pain in humans, including those with cardiac operation and heart failure (14, 16, 24) . However, there is little evidence regarding pentazocine action on myocardial contractility in heart because of lacking in vivo studies using rodents. In isolated cardiomyocytes, 1 nM of (ϩ) pentazocine slightly reduces contraction amplitude, whereas 10 nM of the drug increases contraction amplitude. The increase in contraction amplitude is transient (23) . The ameliorated effect of pentazocine after cardiac ischemia is reported in the Langendorff-perfused isolated heart preparation (27) . Moreover, pentazocine shows cardioprotective effects in human or rodents after cardiac surgery (3, 14, 21, 33) . Although the previous studies suggested that pentazocine regulates Ca 2ϩ mobilization from sarcoplasmic reticulum (SR)/endoplasmic reticulum (ER) through opioid or -1 receptors ( 1 R) (8, 23) , the precise cardioprotective mechanisms of pentazocine in cardiomyocytes remain unclear. Because pentazocine is a weak competitive antagonist of the -type opioid receptor and strong agonist for -and ␦-receptors (9) in addition to a potent 1 R agonist (19) , it is important to define which receptors mediate pentazocine-induced cardioprotection.
Recently, we reported relatively high expression of 1 R in rat heart compared with brain and aortic tissues (6) . Others reported in vivo studies indicating that 1 R expression in heart is upregulated by stress stimuli, such as immobilization and hypoxia (23) . By contrast, we noted markedly reduced 1 R levels in the left ventricle (LV) following heart failure in transverse aortic constriction (TAC) mice (30) . Furthermore, we confirmed a significant positive correlation between reduced 1 R expression in heart and impaired cardiac function, as assessed by fractional shortening (30) .
In noncardiomyocytes, 1 R localizes to the mitochondriaassociated ER membrane, and its interaction with the inositol-1,4,5-trisphosphate (IP 3 ) receptor (IP 3 R) promotes Ca 2ϩ transport into mitochondria from the ER (11) . The increased Ca 2ϩ transport into mitochondria resulted in decreased Ca 2ϩ release to cytosol through type 2 IP 3 R (IP 3 R2) in cardiomyocytes (11) . Thus regulation of intracellular Ca 2ϩ mobilization by 1 R may play pivotal roles in the antihypertrophic effect of 1 R agonists. Because IP 3 R2 is the most prominent isoform in the heart (2, 17) , and its expression is upregulated following cardiac hypertrophy in both humans and rodents (1, 10, 22) , the suppression of IP 3 R2-mediated Ca 2ϩ release to cytosol by 1 R is particularly important. In addition to the critical role of IP 3 R2-mediated Ca 2ϩ release in the development of cardiac hypertrophy, ryanodine receptor (RyR)-mediated Ca 2ϩ release or leak is also crucial for cardiac hypertrophy (12, 34) . Notably, cardiomyocytes from RyR-R176Q knockin mice, a mutation that increases catecholamine-induced SR Ca 2ϩ release in ventricular myocytes (13) , show increased Ca 2ϩ leakage from the SR after TAC, leading to cardiac hypertrophy (32) . In addition, RyR-2 heterozygous (RyR ϩ/Ϫ ) knockout (KO) mice show reduced hypertrophy compared with wild-type mice 3 wk after TAC (34) . However, the functional role of 1 R in regulation of RyR-mediated Ca 2ϩ release/leakage during development of heart failure remains unclear.
To evaluate the clinical relevance of pentazocine on hypertrophy, we investigate pentazocine-mediated cardioprotection via 1 R and the diverse regulation of IP 3 R2 and type 2 RyR (RyR2) functions by 1 R stimulation ovariectomized and pressure-overload (OVX-PO) female rats (4, 5) . We defined that 1 Animals. All animal-handling procedures complied with the Guide for Care and Use of Laboratory Animals and were approved by the Animal Experimentation Committee of Tohoku University Graduate School of Pharmaceutical Sciences. All efforts were made to reduce animal suffering and minimize the number of animals used. Female 6-wk-old Wistar rats weighing 150 -200 g were obtained from Japan SLC (Hamamatsu, Japan). Rats were housed under climatecontrolled conditions with a 12-h:12-h light/dark cycle and provided with standard food and water ad libitum. An acclimation period of at least 1 wk was provided before initiating the experimental protocol.
Surgical procedures. Bilateral OVX was performed in rats anesthetized with pentobarbital sodium (50 mg/kg, ip) (Tokyo Kasei Kogyo, Tokyo, Japan) as we previously described (5) . Two weeks after sham operation or OVX, pressure-overload was initiated in both groups by abdominal aortic banding, as we previously described (5) . Briefly, rats were anesthetized, the abdominal aorta was exposed under sterile conditions through a midline abdominal incision, and a blunted 25-gauge needle (outside diameter, 0.5 mm) was placed between the right and left renal arteries. A ligature (6 -0 silk) was snugly tied around both the abdominal aorta and needle. The needle was then removed, leaving the internal diameter of the aorta approximately equal to that of the needle. The sham operation was performed in OVX rats, and an untied ligature was placed at same location. After surgery, animals were housed under controlled environmental conditions with food (Purina Formulab Chow 5008; Purina, St. Louis, MO) and water ad libitum. Adequate depth of anesthesia was confirmed by a negative toe-pinch reflex. If anesthesia was not sufficient, then a top-up dose of 20% of the initial dose was given.
Experimental design. Separated female Wistar rats were randomly assigned to six groups: 1) OVX (7 rats); 2) OVX plus pentazocine (1.0 mg/kg) (OVXϩP 1.0) (4 rats); 3) OVX plus PO plus vehicle (OVXPOϩVehicle) (7 rats); 4) OVX plus PO plus pentazocine (0.5 mg/kg) (OVX-POϩP 0.5) (6 rats); 5) OVX plus PO plus pentazocine (1.0 mg/kg) (OVX-POϩP 1.0) (6 rats); 6) OVX plus PO plus pentazocine (1.0 mg/kg) plus NE-100 (1.0 mg/kg) (OVX-POϩSAϩNE) (6 rats).
Drug administration. Pentazocine and NE-100 were dissolved in a 0.9% saline solution. Pentazocine (0.5-1.0 mg/kg ip) and NE-100 (1.0 mg/kg po) were administered for 4 wk (once daily) in a volume of 1 ml/1 kg of body of mice, beginning at 1 day after aortic banding.
Measurement of cardiac hypertrophy. Animals were killed after 4 wk of drug or vehicle treatment. To do so, rats were weighed and anesthetized with pentobarbital sodium (50 mg/kg ip). The thoracic cavity was opened, and hearts were immediately harvested and weighed. Cardiac indices, expressed as the heart weight (in milligrams) to body weight (in grams) ratio (HW/BW), were used to estimate the degree of cardiac hypertrophy.
Real-time PCR analysis. Cardiac gene expression was analyzed by real-time RT-PCR as described previously (29) . Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) from LV after 4 wk of PO in OVX female rats. Two micrograms of total RNA was reverse-transcribed using the Reverse Transcription system (Promega, Madison, WI) according to the manufacturer's protocol. Primer sequences for ANP were as follows: 5=-gtccaacacagatctgatgg-3= and 5=-gatttggctgttatcttcgg-3=, generating a 377-base pair product. Primer sequences for rat GAPDH were as follows: sense, 5=-agaacatcatccctgcatcc-3=; antisense, 5=-acattgggggtaggaacac-3=. PCR amplification was performed using the GeneAmp PCR system 9700 (Applied Biosystems Japan, Chiba, Japan). PCR conditions (98°C for 30 s and 34 cycles of 95°C for 10 s, 60°C for 1 min, and 65°C for 1 min) were determined to be within the linear amplification range.
Masson's trichrome stain. Scar formation in the LV of female rats was evaluated by Masson's trichrome stain kit (Sigma) according to the manufacturer's protocol.
Hemodynamic measurements. Hemodynamic measurements were done as we previously described (5, 29) . Briefly, rats were anesthetized with pentobarbital sodium (50 mg/kg ip). The right carotid artery was cannulated with a polyethylene catheter (PE-50, length 25 cm) filled with degassed saline containing heparin (300 UI/ml). The probe to measure arterial blood pressure was placed in the region of origin of the aortic arch. Hemodynamic variables were measured with a pressure transducer (Nihon Kohden, Tokyo, Japan) connected to a polygraph (Nihon Kohden, Tokyo, Japan) and recorded using a thermal recorder (Nihon Kohden, Tokyo, Japan). Meticulous care was taken to ensure that the system remained free of air bubbles during the experimental period. After arterial blood pressure (Ap-601G; Nihon Kohden, Tokyo, Japan) and heart rate (HR) (AT-601G; Nihon Kohden, Tokyo, Japan) measurements were obtained through the polygraph, the catheter was advanced to the LV cavity. We then measured LV systolic and end-diastolic pressures (AP-601G; Nihon Kohden, Tokyo, Japan) (LVEDP), the maximal rate of pressure development (ϩdp/dt), and the rate of relaxation (-dp/dt) of the LV by cardiotachometer (EQ-601G; Nihon Kohden) using the polygraph.
Immunohistochemistry. Immunohistochemistry was carried out using a previously described method (20) . Rat heart tissues were embedded in optimal cutting temperature compound (Sakura, Torrance, CA). After a wash with this compound, slides were treated with 0.5% Blocking Reagent (PerkinElmer, Waltham, MA) (for 1 h). For immunocytochemistry, 20-m sliced heart tissues were incubated 7 days at 4°C with anti-1R antibody (1:500) and anti-IP3R2 antibody (1:200) or anti-RyR antibody (1:200) in 0.5% blocking reagent. After being washed, tissue sections were incubated for 24 h with a species-specific secondary antibody with Alexa 594 and Alexa 488 in 0.5% blocking reagent. Sections of rat heart tissue embedded in VECTASHIELD (Vector Laboratories, Burlingame, CA) were examined using a fluorescence microscope. Immunofluorescent images were obtained with confocal laser scanning microscope (TCS SP; Leica Microsystems, Wetzlar, Germany).
Preparation of primary cultures. Neonatal rat ventricular cardiomyocytes were isolated from hearts of 1-to 5-day-old Wistar rats that had been killed by decapitation, and cardiomyocytes were cultured as described (30, 31) . Briefly, rat pups were decapitated, and their hearts were removed immediately. Ventricles were separated from heart and washed in Hank's balanced salt solution (137.0 mM NaCl, 5.4 mM KCl, 0.4 mM KH2PO4, 0.3 mM Na2HPO4·12H2O, 6.12 mM glucose, 4.2 mM NaHCO3), and myocytes were dissociated from the ventricles by serial digestion with 0.1% trypsin and 0.05% DNAase I in the same solution. After each digestion, dissociated cardiomyocytes were collected and suspended in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS) and 0.02% trypsin. Cells were collected by centrifugation (4°C, 1,000 g for 10 min). After the supernatant was removed, DMEM containing 10% FBS was added. Cells were gently agitated and then plated on uncoated 90-mm culture dishes. Plates were allowed to stand for 90 min at 37°C in a CO2 incubator to remove nonmyocytes, which attached to the culture plates. Unattached myocytes were collected and plated at a density of 1-2 ϫ 10 6 cells per 5-mm dish in in 10% FBS in DMEM. Cells were cultured in serum-free DMEM before treatment with angiotensin II (Ang II) (100 nM).
Morphological analysis in NRVMs. Cultured NRVMs were plated on collagen-coated glass slides at a density of 1-2 ϫ 10 6 cells per coverslip of 12-mm diameter. After incubation in the presence or absence of Ang II for 48 h, cultured cells were washed three times in PBS (pH 7.4) and fixed with 4% formaldehyde. After permeabilization with 0.1% Triton X-100 in PBS, fixed cells were incubated with 1% bovine serum albumin in BS for 30 min. For cell size measurement, cardiomyocytes were incubated for 3 h at room temperature with rhodamine-conjugated phalloidin (1:300; Molecular Probes, Eugene, OR) in PBS containing 1% BSA. After cell images were acquired using an Olympus fluorescence microscope, the surface area of cells was quantitated using the Image J program. All cells from randomly selected fields were examined in each condition (at least 100 myocytes per group). The surface area of control cells was set at 100% and compared with that of treated cells.
Crosslinking and immunoprecipitation. Crosslinking was performed as Hayashi et al. (11) have done previously. Briefly, heart tissue were prepared in 50 mM Tris (pH 7.4) containing 0.2% CHAPS and protease inhibitors. Crosslinking was performed by incubating cell suspensions in ice-cold PBS with 150 g/ml dithiobis (succinimidylpropionate) for 60 min. Reaction was stopped by adding Tris (pH 8.8, final 50 mM). Fifteen minutes after incubation on ice, lysates were lysed with 0.5% Triton X-100. Immunoprecipitation analysis was then performed as previously described (28) .
Western blot analysis. Dissected LV tissue samples were rapidly frozen in liquid nitrogen and stored at Ϫ80°C before analysis. For assays, each frozen sample was homogenized as described (29 -31) .
Measurement of ATP content in vivo. Four weeks after aortic banding, rats were anesthetized, and hearts were excised and quickly perfused with PBS to wash out blood from coronary vessels. Heart tissue was sliced at 2-mm thickness using a slicer (RBS-2; ZivicMiller Laboratories, Zelienople, PA). LV tissue samples were then rapidly frozen in liquid nitrogen and stored at Ϫ80°C before use. ATP measurement was performed using an ATP assay kit (Tokyo Ink, Tokyo, Japan), according to the manufacturer's protocol as described (28, 31) . Briefly, frozen samples were homogenized in homogenate buffer (0.25 M sucrose, 10 mM HEPES-NaOH, pH 7.4), and lysates were cleared by centrifugation at 1,000 g for 10 min at 4°C. The supernatant was collected, and supernatant proteins were solubilized in extraction buffer. After 30 min, luciferin buffer was added to each sample, and oxyluciferin was detected using a luminometer (Gene Light 55; Microtec, Funabashi, Japan).
Measurement of intracellular Ca 2ϩ using Fura-2. Intracellular Ca 2ϩ measurement was performed as described (28, 31) . NRVMs were cultured on glass coverslips and maintained in growth medium. After stimulation with 1 M pentazocine for 1 h, myocytes were loaded with the Ca 2ϩ -sensitive dye Fura-2 acetoxymethyl ester (2.5 M) for 30 min before measuring Ca 2ϩ levels in a chamber on the stage of an inverted microscope. Cells were perfused with normal Tyrode solution containing 150 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5.6 mM glucose, and 5 mM HEPES at 37°C. When Ca 2ϩ fluorescence levels reached steady state, 10 M ryanodine was applied for 10 s through a small perfusion pipe and incubated cardiomyocytes to ryanodine during Ca 2ϩ imaging. The amplitude of the ryanodine-induced Ca 2ϩ transient was used as an index of RyRmediated Ca 2ϩ release. Changes in ryanodine-induced Ca 2ϩ release from the SR were determined using a ratio of the fluorescence emission at 530 nm in response to excitation at 340 nm and at 380 nm. The intracellular calcium concentration was monitored and averaged with 20 cells and repeated twice in each condition.
Statistical analysis. Values are represented as means Ϯ SE. Results were evaluated for differences using one-way ANOVA, followed by multiple comparisons using Scheffe's test. P Ͻ 0.05 was considered statistically significant.
RESULTS
Effects of pentazocine administration on morphometric changes. Our previous study indicated that, at 6 wk after OVX alone in rats, the enlargement of heart and lung showing HW/BW and lung weight/body weight (LW/BW) had not been observed, and these parameters are indistinguishable from those in sham-operated controls (4). Thus we used OVX rats as controls in the following studies. As we previously observed (29) , the ratio of HW/BW markedly increased in the OVX-PO (P Ͻ 0.01 vs. OVX) compared with the OVX group (Fig. 1A) . Pentazocine treatment starting at 1 day after aortic banding significantly reduced the elevated HW/BW ratio (P Ͻ 0.01 vs. OVX-PO-vehicle) (Fig. 1A) . LW/BW ratio was also significantly increased in the OVX-PO group (P Ͻ 0.05 vs. OVX) (Fig. 1B) , and pentazocine treatment significantly restored the elevated LW/BW ratio (P Ͻ 0.05 vs. OVX-PO-vehicle) (Fig.  1B) . We did not observe significant changes in BW between any groups (Fig. 1C) . Coadministration of 1 R antagonist NE-100 with pentazocine blocked pentazocine-mediated inhibition of increased HW/BW ratio (P Ͻ 0.01 vs. OVX-PO-P 1.0) and LW/BW ratio (P Ͻ 0.05 vs. OVX-PO-P 1.0) (Fig. 1,  A and B) . We investigated ANP mRNA levels, as a hypertrophy marker. The ANP mRNA was increased following OVX-PO in rats. The chronic oral administration of pentazocine (1.0 mg/kg) restored the increased ANP mRNA levels in OVX-PO rats (Fig. 1D ). Coadministration of NE-100 with pentazocine eliminated its ameliorating effect of pentazocine (Fig. 1D) . These results suggested that pentazocine-induced antihypertrophic activity is mediated by 1 R. We also evaluated pentazocine effect on scar formation by Masson's trichrome stain at 4 wk after aortic banding in OVX rats. Aortic banding in OVX rats significantly increased scar formation. The chronic oral administration of pentazocine (1.0 mg/kg) inhibited the scar formation observed in OVX-PO rats. Coadministration of NE-100 with pentazocine eliminated its ameliorating effect on scar formation.
Effects of pentazocine administration on hemodynamic parameters. We next evaluated LV functions in OVX-PO rats with or without pentazocine administration. Consistent with our previous observations (5, 29), LVEDP (P Ͻ 0.01 vs. OVX) ( Fig. 2A) , LV developed pressure (LVDP) (P Ͻ 0.01 vs. OVX) (Fig. 2B) , rates of LV contraction (ϩdp/dt) (P Ͻ 0.01 vs. OVX) (Fig. 2C) , and rates of LV relaxation (-dp/dt) (P Ͻ 0.01 vs. OVX) (Fig. 2D) were all significantly increased in OVX-PO compared with OVX rats. Pentazocine administration for 4 wk antagonized elevated LVEDP (P Ͻ 0.01 vs. OVX-PO-vehicle) ( Fig. 2A) , LVDP (P Ͻ 0.01 vs. OVX-POvehicle) (Fig. 2B) , and rates of LV contraction (ϩdp/dt) (P Ͻ 0.01 vs. OVX) (Fig. 2C ) and relaxation (-dp/dt) (P Ͻ 0.01 vs. OVX) (Fig. 2D ). Coadministration of NE-100 with pentazocine blocked pentazocine-mediated inhibition of increased LVEDP, LVDP, and LV contraction and relaxation (Ϯdp/dt) (Fig. 2, A-D) . Pentazocine treatment for OVX rats had no effects on cardiac function (Fig. 2, A-D) . These findings suggest that pentazocine-induced cardioprotective effects are largely mediated by the 1 R.
Similarly, OVX-PO treatment significantly increased both mean arterial blood pressure (MABP) (P Ͻ 0.01 vs. OVX) (Fig. 2E ) HR (P Ͻ 0.05 vs. OVX) (Fig. 2F ) compared with OVX rats. Pentazocine administration improved elevated MABP (P Ͻ 0.01 vs. OVX-PO-vehicle) (Fig. 2E ) and HR (P Ͻ 0.05 vs. OVX-PO-vehicle) (Fig. 2F ). Coadministration of NE-100 with pentazocine blocked pentazocine-mediated inhibition of increased MABP and HR (P Ͻ 0.01 vs. OVX-PO-P 1.0) (Fig. 2, E and F) . Pentazocine treatment for OVX rats had no effects on cardiac function (Fig. 2, E and F) .
Effects of pentazocine administration on 1 R and IP 3 R expression and localization in the LV. We previously reported that elevation of 1 R expression by fluvoxamine is associated with fluvoxamine-mediated amelioration of cardiac dysfunction in hypertrophied heart (6). As expected, pentazocine treatment significantly and dose dependently restored 1 R levels (P Ͻ 0.05 vs. OVX-PO-vehicle for P Ͻ 0.5 and P Ͻ 0.01 vs. OVX-PO-vehicle for P Ͻ 1.0) (Fig. 3, A and B) . By contrast, PO-induced hypertrophy was associated with increased IP 3 R2 expression levels in the LV (P Ͻ 0.05 vs. OVX). Pentazocine administration significantly and dose dependently decreased IP 3 R2 expression levels (P Ͻ 0.05 vs. OVX-POvehicle for P Ͻ 0.5 and P Ͻ 0.01 vs. OVX-PO-vehicle for P Ͻ 1.0) (Fig. 3, A and B) . Although coadministration of NE-100 with pentazocine abolished pentazocine-mediated cardioprotective effects (Figs. 1 and 2 ), coadministration of NE-100 did not abolish pentazocine-mediated increases in 1 R expression (P Ͻ 0.01 vs. OVX-PO-vehicle) in the LV (Fig. 3 , A and B). On the other hand, coadministration of NE-100 with pentazocine totally abolished pentazocine-mediated decreases in IP 3 R2 expression (Fig. 3, A and B) .
In the present study, we also confirmed the diverse changes in 1 R and IP 3 R2 expression by immunohistochemical study. The 1 R and IP 3 R2 were homogeneously expressed in the cardiomyocytes, in which the 1 R is likely colocalized with IP 3 R2 in ER membranes (Fig. 3C) . Interestingly, 1 R immunofluorescence disappeared after OVX-PO, whereas IP 3 R2 immunofluorescence markedly increased in the enlarged cytoplasm (Fig. 3C) , suggesting decreased association between IP 3 R2 and 1 R. Importantly, pentazocine administration inhibited OVX-PO-induced reduced 1 R expression and the increased IP 3 R2 expression (Fig. 3C) , suggesting restoration of IP 3 R2 and 1 R association. Coadministration of NE-100 with pentazocine abolished pentazocinemediated inhibitory effects.
Furthermore, to determine the association of 1 R with IP 3 R2 in physiological and pathological condition, we performed immunoprecipitation assay using OVX-PO female rats LV tissue with or without pentazocine treatment. We observed the 1 R interaction with IP 3 R2 under physiological conditions. We also defined that the percentage of IP 3 R2 interacted with 1 R within the total IP 3 R2 extracted from LV is 12.1% by calculating the IP 3 R2 immunoreactive intensities between immunoprecipitants and heart tissue lysate (Fig. 4A) . OVX-PO-induced hypertrophy triggered decreased interaction between 1 R and IP 3 R2 in the LV (Fig. 4, B and C) . Interestingly, pentazocine administration rescued the reduced interaction of 1 R with IP 3 R2 (Fig. 4, B and C) . Coadministration of NE-100 did not inhibit the pentazocine-mediated increases in 1 R expression, but NE-100 treatment abolished pentazocine-mediated increase in the association of 1 R with IP 3 R2 (Fig. 4, B and C) . Similar results were obtained when IP 3 R2 was immunoprecipitated by 1 
. Effect of pentazocine and NE-100 (NE) on hemodynamic measurements. A: Left ventricular end-diastolic pressure (LVEDP). B: LV developed pressure (LVDP). C: rates of LV contraction (ϩdp/dt). D:
Rates of LV relaxation (-dp/dt). E: mean arterial blood pressure (MABP). F: heart rate (HR). Each group consists of 5-6 rats. Each column represents the mean Ϯ S. *P Ͻ 0.05 and **P Ͻ 0.01 vs. the OVX group; #P Ͻ 0.05 and ##P Ͻ 0.01 vs. the OVX-PO-vehicle-treated group; † †P Ͻ 0.01 vs. the OVX-PO-P 1.0-treated group. (Fig. 4D) . These results suggested that pentazocine-induced restoration of imbalance between 1 R and IP 3 R2 levels is correlated with its cardioprotective activity in animals subjected to OVX-PO-induced cardiac pathological hypertrophy.
Effects of 1 R activation on ATP content in OVX female rats.
We recently reported that treatment with SA4503, the selective 1 R agonist, in Ang II-induced hypertrophied cardiomyocyte promotes IP 3 R-mediated Ca 2ϩ transport into mito- chondria and ATP production (31) . Therefore, we speculated that pentazocine is able to promote cardiac ATP production in OVX-PO rats. Indeed, ATP content of the OVX-PO rat LV was significantly decreased compared with OVX rats (P Ͻ 0.01 vs. OVX) (Fig. 4E ). Pentazocine treatment (1.0 mg/kg) significantly and completely rescued the reduced ATP content (P Ͻ 0.01 vs. OVX-PO-vehicle) (Fig. 4E) , and the effect was completely abolished by coadministration with NE-100 (Fig.  4E ). These observations strongly suggest that pentazocinemediated increases in ATP content are mediated by the 1 R stimulation.
Effects of pentazocine administration on 1 R and RyR expression and localization in the LV.
In addition to IP 3 R2, RyRs are critical role in the cardiac hypertrophy (12) . We next examined whether 1 R regulates RyR2, a major cardiac form in vivo. Our result is the first report showing interaction between RyR2 and 1 R. As expected, RyR2 was colocalized with 1 R under physiological conditions such as OVX treatment alone (Fig. 5A) . We also estimated the amount of RyR2 interacted with 1 R as 11.9% within the total RyR2 protein in heart tissue lysate (Fig. 6A ) because 1 R immunofluorescence disappeared after OVX-PO, whereas the intensity of RyR immunofluorescence was unchanged (Fig. 5A) . However, the interaction of RyR2 with 1R on SR membrane is likely impaired by OXV-PO condition. In contrast with increased IP 3 R2 expression with cardiac hypertrophy, the RyR2 expression levels were unchanged following OVX-PO (Fig. 5, B and  C) . However, the decreased 1 R expression led to reduction of interaction between 1 R and RyR2 in vivo (Fig. 6, B and C) . Pentazocine administration restored the interaction between 1 R and RyR2 as expected (Fig. 6 , B and C). Coadministration of NE-100 with pentazocine abolished pentazocine-mediated enhanced interaction (Fig. 6, B and C) . Similar results were obtained when RyR2 was immunoprecipitated by 1 R antibody (Fig. 6D) .
Effects of pentazocine treatment on Ang II-induced cardiomyocyte hypertrophy and on ryanodine-induced Ca
2ϩ release to the cytosol in NRVMs. Now, it is very important to investigate the effect of pentazocine on RyR2 function of Ca 2ϩ release from SR in cardiomyocytes. Endogenous 1 R was interacted with IP 3 R2 and RyR2 in cultured NRVMs (Fig. 7A) . Cultured NRVMs were incubated with 1.0 M pentazocine for 1 h and then triggered Ca 2ϩ release form SR by ryanodine treatment. Importantly, pentazocine treatment significantly reduced ryanodine-induced Ca 2ϩ release to the cytosol (Fig. 7 , B and C). These results suggested that RyR2 function negatively regulates pentazocine via 1 R, and the inhibitory regulation of RyR2 by 1 R mediates pentazocine-induced antihypertrophic effects on Ang II-induced hypertrophy.
Because pentazocine has affinity for other opioid receptors such as , , and ␦, it is very important to investigate the effects of opioid receptor antagonists on the pentazocine- of 1R and IP3R2 from rat heart lysate. After immunoprecipitation with anti-IP3R2 antibody, immunoprecipitants and heart extracts (lysate) were separated on SDS-PAGE and subjected to Western blot (WB) analysis using anti-1R antibody. The same amounts of proteins from lysate were used for immunoprecipitation. B: immunoprecipitation of 1R and IP3R2 using rat heart lysate. After immunoprecipitation with anti-IP3R2 antibody, immunoprecipitants with heart extracts (lysate) were separated on SDS-PAGE and subjected to Western blot analysis using anti-1R antibody. C: densitometric quantification of immunoreactive bands of 1R immunoprecipitated by IP3R2 in the LV. Data are expressed as percentages of the value of OVX rats and are an average of 3 independent assays. D: immunoprecipitation of 1R and IP3R2 from rat heart lysate. After immunoprecipitation with anti-1R antibody, immunoprecipitants with heart extracts were separated on SDS-PAGE and subjected to Western blot analysis using anti-IP3R2 antibody. mediated antihypertrophic effect. Cultured NRVMs were exposed to Ang II for 48 h with pentazocine with or without opioid receptor antagonist and NE-100. As reported previously (33) , Ang II treatment significantly increased the cell size compared with control cells 48 h after Ang II exposure (P Ͻ 0.01 vs. control) (Fig. 7, D and E) . Pentazocine (0.5-1.0 M) dose dependently inhibited Ang II-induced cell enlargement (P Ͻ 0.01 vs. Ang II) (Fig. 7, D and E) . Importantly, dantrolene treatment (10 M), a RyR antagonist, eliminated the Ang II-induced cardiomyocyte hypertrophy (P Ͻ 0.01 vs. Ang II) (Fig. 7, D and E) , suggesting the involvement of RyR in Ang II-induced hypertrophy. Combined treatment with NE-100 eliminated pentazocinemediated inhibition of cardiomyocyte hypertrophy (P Ͻ 0.01 vs. P Ͻ 1.0) (Fig. 7, D and E) . However, combined treatments of pentazocine with cyprodime (-receptor antagonist), 2-3,4-dichlorophenyl-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl) ethyl] acetamide (-receptor antagonist), or naltrindole (␦-receptor antagonist) did not eliminate pentazocine-mediated inhibition of cardiomyocyte hypertrophy (Fig.  7, D and E) . These findings suggest that pentazocine acts on the cardiac 1 R to antagonize Ang II-induced cardiomyocyte enlargement without effects on another opioid receptors.
DISCUSSION
Pentazocine was clinically used for anesthetic adjunct in the operation, including hypothermic and ischemic myocardial arrest, and postresuscitation myocardial dysfunction is one of the leading causes of early death after initial success of resuscitation (3, 15) . Many reports suggested that pentazocine shows cardioprotective effects in human in the early phase after cardiac surgery or isolated ischemic heart (3, 21, 27, 33) . However, it is unclear whether chronic pentazocine treatment inhibits heart failure following PO-induced hypertrophy. Here, we demonstrated that 1 R stimulation with pentazocine rescues OVX-PO-induced cardiac dysfunction via interaction between 1 R and IP 3 R. Moreover, we found that RyR2 colocalized with 1 R in cardiomyocyte ER/SR membranes. Pentazocine treatment promotes association of RyR2 with 1 R. The association of 1 R negatively regulates ryanodine-induced Ca 2ϩ release from the SR (Fig. 6A) . As expected, these inhibitory actions of 1 R on RyR2 function closely associated with pentazocine-induced antihypertrophic effects on Ang II-induced hypertrophy. This is in contrast with no effects of other opioid receptor antagonists. Benedict et al. (3) suggested that pentazocine protected against myocardial infarction via ␦-receptor stimulation in isolated heart from rabbit (3). However, recent study suggested that selective ␦-receptor stimulation with Tan-67 augments failing heart in Bio 14.6 cardiomyopathic hamster (7) . The discrepancies may be due to different methodologies and cell types used, including in vivo vs. in vitro tests. Our study suggested that pentazocine-induced 1 R stimulation plays an important role for antihypertrophic effects.
We recently demonstrated that OVX-PO-induced cardiomyocyte hypertrophy promotes an imbalance between 1 R and IP 3 R2 expression levels in SR/ER membranes, thereby dysregulating IP 3 R2 function by dissociating it from the 1 R. Hayashi and Su (11) have proposed an attractive model of a 1 R-mediated cytoprotective effect in CHO cells, in which binding of the 1 R to the IP 3 R3 increases Ca 2ϩ entry into mitochondria and promotes cell survival. However, the pathological consequences of dissociation of the 1 R from the IP 3 R3 and the pharmacological activity of 1 R agonists remain unclear. As consistent with the previous study (31) , cardiac ATP content was decreased in OVX-PO rats concomitant with dissociation of 1 R from IP 3 R2 (Fig. 4) . Pentazocine treatment rescued OVX-PO-induced ATP depletion and the dissociation of 1 R from IP 3 R2. Therefore, we conclude that pentazocine enhances IP 3 R2-mediated mitochondrial Ca 2ϩ influx and ATP content as summarized in Fig. 8 .
We also discovered that RyR function is negatively regulated by pentazocine-mediated 1 R stimulation. Dysregulation of RyR-mediated Ca 2ϩ release reportedly promotes cardiac . Effects of pentazocine and NE-100 on 1R/RyR2 association in OVX-PO rat hearts. A: immunoprecipitation analysis of 1R and RyR2 from rat heart lysate. After immunoprecipitation with anti-RyR2 antibody, immunoprecipitants from heart extracts (lysate) were separated on SDS-PAGE and subjected to Western blot analyses using anti-1R antibody. The same amounts of proteins from lysate were used for immunoprecipitation. B: immunoprecipitation analysis of endogenous 1R and RyRs using rat heart lysate. After immunoprecipitation with anti-RyR antibody, immunoprecipitants with heart extracts (lysate) were separated on SDS-PAGE and subjected to Western blot analysis using anti-1R antibody. C: densitometric quantification of immunoreactive bands of immunoprecipitation analysis in the LV. Data are expressed as percentages of the value of sham-treated OVX rats and are an average of 3 assays. Data are expressed as percentages of the value of OVX rats. Each column represents the mean Ϯ SE. *P Ͻ 0.05 vs. OVX group; #P Ͻ 0.05 vs. the OVX-PO-vehicletreated group; †P Ͻ 0.05 vs. the OVX-PO-P 1.0-treated group. D: immunoprecipitation analyses of 1R and RyR2 using rat heart lysate. After immunoprecipitation with anti-1R antibody, immunoprecipitants with heart extracts were separated on SDS-PAGE and subjected to Western blot analysis using anti-RyR2 antibody.
hypertrophy in vivo as reported previously (34) . For example, RyR-2 heterozygous (RyR ϩ/Ϫ ) KO mice show reduced hypertrophy compared with wild-type mice 3 wk after TAC (34 IP 3 R-mediated Ca 2ϩ release through dysregulation of the 1 R possibly accounts for Ca 2ϩ leakage from the SR (22) . In addition, RyR-mediated SR Ca 2ϩ leakage is also a critical factor in abnormal intracellular Ca 2ϩ handling that contributes hypertrophy and heart failure (12, 18) . A recent study confirmed that RyR is phosphorylated at Ser2814 by Ca 2ϩ /calmodulin-dependent kinase II, thereby promoting Ca 2ϩ leak from SR and TAC-induced heart failure (26) . Knockin mice with an inactivated Ser2814 phosphorylation site protected from TAC-induced heart failure progression (26) . Our present study also suggested that dantrolene treatment, a RyR antagonist, rescues Ang II-induced cardiomyocyte hypertrophy. This is consistent with the recent report in which dantrolene administration (5 mg/kg ip) inhibits PO-induced cardiac hypertrophy in rats (25) .
In addition, we recently reported that a specific 1 R agonist, SA4503, inhibits IP 3 R-mediated SR Ca 2ϩ release into the cytosol in cardiomyocytes (31) . Thus we propose that pentazocine treatment suppresses both IP 3 R-and RyR-mediated SR Ca 2ϩ release or leakage into cytosol or nucleus, thereby inhibiting hypertrophy-related gene expression through calcineurin. Taken together, pentazocine-induced suppression of Ca 2ϩ leakage from SR by 1 R stimulation can explain the potent antihypertrophic effects. However, further extensive studies are required to identify mechanisms underlying regulation of RyR2-mediated Ca 2ϩ release into the cytosol by 1 R. We should also define the association regions between 1 R and RyR2 in future study.
In conclusion, our current hypothesis is summarized in Fig.  8 . Under normal conditions in naïve cardiomyocytes, 1 R is associated both with RyR2 and IP 3 R2 in SR membranes. Pentazocine treatments suppress RyR2-mediated Ca 2ϩ release from SR, leading to suppression of overconstriction. Our previous studies also defined that 1 R stimulation suppresses Ca 2ϩ release through IP 3 R2 in cardiomyocytes. On the other hand, 1 R stimulation promotes mitochondrial Ca 2ϩ transport through IP 3 R2 and in turn ATP production (31). However, under pathological conditions following prolonged hypertrophic stimuli, such as humoral stress and pressure overload, 1 R is markedly downregulated in cardiomyocytes. Therefore, dysregulation of IP 3 R2 and RyR2 promotes Ca 2ϩ leakage from SR, and mitochondrial ATP production is largely impaired. The reduced mitochondrial Ca 2ϩ entry likely promotes radical oxidative stress-induced mitochondrial dysfunction. Importantly, SA4503 (31) and pentazocine (in the present study) suppress Ca 2ϩ leakage from SR and restore ATP production by stimulating mitochondrial Ca 2ϩ transport from SR. Taken together, 1 R stimulation with pentazocine inhibits cardiac hypertrophy and dysfunction by restoring both IP 3 R-mediated mitochondrial ATP production and RyR-mediated Ca 2ϩ leakage via 1 R stimulation. Fig. 8 . Schematic representation of 1R-mediated protection of cardiac hypertrophy. Pentazocine treatments suppress RyR2-mediated Ca 2ϩ release from sarcoplasmic reticulum (SR), leading to suppression of overconstriction. Our previous studies also defined that 1R stimulation suppresses Ca 2ϩ release through IP3R2 in cardiomyocytes. On the other hand, 1R stimulation promotes mitochondrial Ca 2ϩ transport through IP3R2 and in turn ATP production (31) . However, under pathological conditions following prolonged hypertrophic stimuli, such as humoral stress and PO, 1R is markedly downregulated in cardiomyocytes. Therefore, dysregulation of IP3R2 and RyR2 promote Ca 2ϩ leakage from SR, and mitochondrial ATP production is largely impaired. The reduced mitochondrial Ca 2ϩ entry likely promotes radical oxidative stress-induced mitochondrial dysfunction. Importantly, SA4503 (31) and pentazocine (in the present study) suppress Ca 2ϩ leakage from SR and restore ATP production by stimulating mitochondrial Ca 2ϩ transport from SR.
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